tetano
Editor, Senior Moderator
Ann Epidemiol
. 2024 Feb 19:S1047-2797(24)00031-0.
doi: 10.1016/j.annepidem.2024.02.007. Online ahead of print. The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020-2022
Colleen MacCallum-Bridges[SUP] 1 [/SUP], Jana L Hirschtick[SUP] 2 [/SUP], Akash Patel[SUP] 3 [/SUP], Robert C Orellana[SUP] 4 [/SUP], Michael R Elliott[SUP] 5 [/SUP], Nancy L Fleischer[SUP] 6 [/SUP]
Affiliations
Purpose: To estimate the association between COVID-19 vaccination status at the time of COVID-19 onset and long COVID prevalence.
Methods: We used data from the Michigan COVID-19 Recovery Surveillance Study, a population-based probability sample of adults with COVID-19 (n=4,695). We considered 30-day and 90-day long COVID (illness duration ≥30 or ≥90 days, respectively), using Poisson regression to estimate prevalence ratios (PRs) comparing vaccinated (completed an initial series ≥14 days before COVID-19 onset) to unvaccinated individuals (received 0 doses before COVID-19 onset), accounting for differences in age, sex, race and ethnicity, education, employment, health insurance, and rurality/urbanicity. The full unvaccinated comparison group was further divided into historic and concurrent comparison groups based on timing of COVID-19 onset relative to vaccine availability. We used inverse probability of treatment weights to account for sociodemographic differences between groups.
Results: Compared to the full unvaccinated comparison group, the adjusted prevalence of 30-day and 90-day long COVID were lower among vaccinated individuals [PR[SUB]30-day[/SUB]=0.57(95%CI:0.49,0.66); PR[SUB]90-day[/SUB]=0.42(95%CI:0.34,0.53)]. Estimates were consistent across comparison groups (full, historic, and concurrent).
Conclusions: Long COVID prevalence was 40-60% lower among adults vaccinated (vs. unvaccinated) prior to their COVID-19 onset. COVID-19 vaccination may be an important tool to reduce the burden of long COVID.
Keywords: Cardiovascular disease; EHR; Centers for Disease Control and Prevention; CI; Chronic obstructive pulmonary disease; COVID-19; Confidence interval; COPD; Coronavirus disease 2019; CVD; Electronic health record; IPTW; Inverse probability of treatment weight; MDSS; Messenger ribonucleic acid; NH; Michigan COVID-19 Recovery Surveillance Study; mRNA; Michigan Disease Surveillance System; MI CReSS; Non-Hispanic; PCR; Polymerase chain reaction; PR; Post-acute COVID-19 syndrome; COVID-19; COVID-19 vaccines; Population-based ABBREVIATIONS AND ACRONYMS: CDC; Prevalence ratio; US; United States; WHO World Health Organization..
. 2024 Feb 19:S1047-2797(24)00031-0.
doi: 10.1016/j.annepidem.2024.02.007. Online ahead of print. The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020-2022
Colleen MacCallum-Bridges[SUP] 1 [/SUP], Jana L Hirschtick[SUP] 2 [/SUP], Akash Patel[SUP] 3 [/SUP], Robert C Orellana[SUP] 4 [/SUP], Michael R Elliott[SUP] 5 [/SUP], Nancy L Fleischer[SUP] 6 [/SUP]
Affiliations
- PMID: 38382771
- DOI: 10.1016/j.annepidem.2024.02.007
Purpose: To estimate the association between COVID-19 vaccination status at the time of COVID-19 onset and long COVID prevalence.
Methods: We used data from the Michigan COVID-19 Recovery Surveillance Study, a population-based probability sample of adults with COVID-19 (n=4,695). We considered 30-day and 90-day long COVID (illness duration ≥30 or ≥90 days, respectively), using Poisson regression to estimate prevalence ratios (PRs) comparing vaccinated (completed an initial series ≥14 days before COVID-19 onset) to unvaccinated individuals (received 0 doses before COVID-19 onset), accounting for differences in age, sex, race and ethnicity, education, employment, health insurance, and rurality/urbanicity. The full unvaccinated comparison group was further divided into historic and concurrent comparison groups based on timing of COVID-19 onset relative to vaccine availability. We used inverse probability of treatment weights to account for sociodemographic differences between groups.
Results: Compared to the full unvaccinated comparison group, the adjusted prevalence of 30-day and 90-day long COVID were lower among vaccinated individuals [PR[SUB]30-day[/SUB]=0.57(95%CI:0.49,0.66); PR[SUB]90-day[/SUB]=0.42(95%CI:0.34,0.53)]. Estimates were consistent across comparison groups (full, historic, and concurrent).
Conclusions: Long COVID prevalence was 40-60% lower among adults vaccinated (vs. unvaccinated) prior to their COVID-19 onset. COVID-19 vaccination may be an important tool to reduce the burden of long COVID.
Keywords: Cardiovascular disease; EHR; Centers for Disease Control and Prevention; CI; Chronic obstructive pulmonary disease; COVID-19; Confidence interval; COPD; Coronavirus disease 2019; CVD; Electronic health record; IPTW; Inverse probability of treatment weight; MDSS; Messenger ribonucleic acid; NH; Michigan COVID-19 Recovery Surveillance Study; mRNA; Michigan Disease Surveillance System; MI CReSS; Non-Hispanic; PCR; Polymerase chain reaction; PR; Post-acute COVID-19 syndrome; COVID-19; COVID-19 vaccines; Population-based ABBREVIATIONS AND ACRONYMS: CDC; Prevalence ratio; US; United States; WHO World Health Organization..